A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy characterized by an aberrant clonal expansion of undifferentiated myeloid blasts. Studies have shown that leukemia stem cells (LSCs) contribute to relapse after chemotherapeutic treatment. [1] Like normal hematopoietic stem cells (HSCs), LSCs maintain their self-renewal ability while generating clonogenic leukemic progenitors capable of producing leukemic cells [2]. Anti-proliferative chemotherapeutic agents commonly target the rapidly cycling leukemic cells, but they generally are ineffective against the quiescent LSCs, partly because of enhanced drug efflux in LSCs [3].
Source: Leukemia Research - Category: Hematology Authors: Dandan Li, Tara L. Lin, Brea Lipe, Richard A. Hopkins, Heather Shinogle, Omar S. Aljitawi Tags: Research paper Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Study